CPC Scientific Advances Green Chemistry Approaches for Scalable TIDES Manufacturing

CPC Scientific, a premier peptide and oligonucleotide-focused Contract Research, Development, and Manufacturing Organization (CDRMO) and a wholly owned subsidiary of Medtide Inc. (HKEX: 3880.HK), has established green chemistry as a core focus of its process development strategy.

This approach aligns with a broader industry effort to make solid-phase peptide synthesis (SPPS) and large-scale API production more sustainable by improving process efficiency, reducing waste, and lowering solvent demand without compromising quality, speed, or cost.

Green Chemistry and Sustainability in TIDES Production

The rapid expansion of commercial-scale TIDES programs, driven in part by growing demand for GLP-1 and other metabolic therapeutics, is increasing pressure on the pharma industry to reduce solvent consumption, minimize waste, and improve process efficiency across the full manufacturing lifecycle.

As production of peptide- and oligonucleotide-based therapeutics continues to scale, the environmental footprint of manufacturing has become an increasingly important consideration for CDMOs, innovators, and their partners.

Solid-phase peptide synthesis (SPPS) is solvent-intensive by nature. Large volumes of dimethylformamide (DMF) and other process solvents are typically required to support coupling, deprotection, and washing steps at scale. DMF represents one of the largest contributors to the environmental footprint of SPPS because of the volumes required, while also representing a significant cost driver in peptide manufacturing.

CPC Scientific’s Approach

CPC Scientific has addressed this challenge through targeted process innovation. The company has developed a DMF recycling strategy for SPPS designed to reduce overall solvent demand while maintaining the process robustness required for scalable peptide manufacturing.

The work demonstrates how green chemistry principles can be integrated into large-scale synthesis while supporting both sustainability objectives and manufacturing economics.

This initiative sits alongside a related CPC Scientific case study in which advanced process improvements across synthesis, cleavage, and final purification enabled multi-kilogram delivery of a GMP-relevant decapeptide program on a tight timescale. By improving process efficiency and reducing manufacturing burden, the approach generated meaningful cost efficiencies for the client while strengthening the resulting product’s market competitiveness.

Together, this body of work reflects CPC Scientific’s wider “going with the compound” strategy: aligning capacity expansion, technical investment, and regulatory infrastructure with the expectation that a growing number of clinical-stage peptide and oligonucleotide programs will advance toward commercial production over the next three to five years.

For CPC Scientific, sustainable process design is treated as a core element of scale-up readiness rather than a downstream optimisation step.

Sharing the Approach with the Industry

CPC Scientific’s green chemistry work has also featured prominently in its industry engagement. At NextGen Biomed 2026 in London, the company presented a case study exploring how SPPS process innovations can support greener and more efficient peptide manufacturing at scale.

At TIDES USA 2026, John Phipps, Vice President of Clinical Pipeline Development, presented on Innovative Peptide Manufacturing Methods That Scale.

These initiatives reflect CPC Scientific’s broader focus on applying efficiency improvements across the expanding TIDES landscape, including increasingly complex peptide, oligonucleotide, and conjugate modalities.

This combination of applied R&D and public knowledge-sharing underlines a broader industry priority: for CDMOs operating at commercial scale, sustainability increasingly needs to be demonstrated, not just claimed.

Meet CPC Scientific

Industry decision makers looking to discuss sustainable peptide and oligonucleotide manufacturing directly with the CPC Scientific team can do so at several upcoming industry events, including:

• CPHI Korea— Seoul, South Korea (25–27 August 2026)
• RNA Leaders USA Congress— Boston, MA (23–25 September 2026)
• BioJapan— Yokohama, Japan | 7–9 October 2026

Resources

See the following CPC Scientific publications to learn more:

GMP Peptides & Oligonucleotides brochure
Oligonucleotide Manufacturing brochure
CPC Scientific: CDMO By the Numbers infographic
White paper: Toward Greener Peptide Manufacturing – Advancing DMF Efficiency in SPPS
White paper: Enabling Sustainable Large-Scale SPPS Through Process Innovations
Click on CPC Scientific News and Articles to see latest News & Events.